Spilled Blood: CSL & Talecris Terminate Their Merger Deal In Face of FTC Lawsuit
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies decide it is not worth the cost and time to battle the FTC in court; the derailed deal may signal tougher times for pharma mergers.
You may also be interested in...
Grifols To Divest Factor VIII Product Koate To Merge With Talecris
Italian company Kedrion will get the Factor VIII product Koate and a fractionation facility in Melville, N.Y., under a consent agreement with the Federal Trade Commission.
Grifols To Divest Factor VIII Product Koate To Merge With Talecris
Italian company Kedrion will get the Factor VIII product Koate and a fractionation facility in Melville, N.Y., under a consent agreement with the Federal Trade Commission.
FTC Taking A Closer Look At Talecris/Grifols Merger; HIGPA Voices Concerns
The Federal Trade Commission has requested further information from both Talecris Biotherapeutics and Grifols in relation to the two companies' proposed merger